Company research
Generate Biomedicines, Inc.
CIK 2100782Updated Nov 14, 2026
GENB price & chart
Loading TradingView…
NASDAQ:GENB on TradingView ↗About the company
Generate (Nasdaq: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better drug candidates for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more at www.generatebiomedicines.com or follow us on X, LinkedIn, and YouTube.
In the news
AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts ↗
Generate Biomedicines Inc. to Participate in Goldman Sachs 47th Annual Global Healthcare Conference ↗
Seeking Alpha
Nvidia boosts SpaceX stake, cuts Intel holding by 25% in Q3 ↗
Generate Biomedicines, Inc. reports Q3 results ↗
Generate Biomedicines: Zealand Deal For Obesity Programs May Not Be Quite What It Seems ↗
SEC disclosures
Generate Biomedicines, Inc. files 8-K: Material Event ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
SCHEDULE 13G - filed by FMR LLC regarding Generate Biomedicines, Inc.
4 filing
144 filing
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Offerings
Registration 333-293204
Filing attachments
ck0002100782-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD Zealand Pharma collaboration provides $30 million upfront, $35 million in early preclinical milestones and nearly $1.2 billion in total potential milestones, plus tiered royalties Anthropic collabo…
Read attachment ↗ck0002100782-ex99_1.htm · 8-K · 2026-08-26
EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients. Dave Singh1, Kapil Mayawala2, Victoria Szenes2, Andreas Eich3, Brian Leaker4, Philipp Badorrek5, Stanislav Ignatenko6, Sacha Prashad2, Stephanie Straley2, Antonios Aliprantis7, Lovely Goyal2, Alex Synder2, Oliver Kornmann3 Affiliations: 1University of Manchester, Ma…
Read attachment ↗ck0002100782-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort …
Read attachment ↗ck0002100782-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (M…
Read attachment ↗ck0002100782-ex4_1.htm · S-1/A · 2026-02-13
Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.001 Generate: Biomedicines Certificate Number ZQ00000000 COMMON STOCK Shares * 000000 **** 000000 ******* ******* 000000 ********* ** 000000 ********* ****** 000000 * Generate Biomedicines, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr. Alexander David Sample SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 370920 10 0 is the owner of **000000**Shares**** ***ZERO HUNDRED THOU…
Read attachment ↗ck0002100782-ex4_3.htm · S-1/A · 2026-02-13
Exhibit 4.3 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of May 9, 2023, by and among Generate Biomedicines, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (each of which is referred to in this Agreement as an “Investor”, and together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsection 6.9, the “In…
Read attachment ↗